Tisotumab Vedotin provides an antibody-drug conjugate (ADC) targeting tissue factor (TF) for ADC and oncology research that specifically combines a tissue factor-directed monoclonal antibody with the microtubule-disrupting payload monomethyl auristatin E (MMAE).
Key Features and Benefits
- Antibody-Drug Conjugate: Combines a tissue factor-targeting monoclonal antibody with the cytotoxic payload MMAE.
- Tissue Factor Targeting: Supports research specifically involving tissue factor expression, binding, internalization, and targeted delivery.
- MMAE Payload: Contains monomethyl auristatin E, a potent microtubule-disrupting agent widely studied in ADC research.
- Protease-Cleavable Linker: Uses a cleavable linker specifically designed to facilitate intracellular payload release following ADC internalization.
- Targeted Payload Delivery: Supports investigation of antibody-mediated MMAE delivery to tissue factor-expressing cells.
- ADC Research Platform: Enables studies of target engagement, cellular uptake, payload release, and ADC activity.
- Oncology Research: Supports investigation of tissue factor biology and ADC mechanisms in cancer research models.
Applications
- ADC Research: Supports studies of antibody-drug conjugate targeting, internalization, and payload delivery.
- Tissue Factor Research: Useful for investigating tissue factor expression, function, and antibody-mediated targeting.
- Cancer Biology Research: Supports studies involving tissue factor-expressing cancer models and related cellular pathways.
- Targeted Drug Delivery: Useful for investigating antibody-mediated delivery of cytotoxic payloads.
- Cell-Based Assays: Supports evaluation of binding, internalization, cellular response, and ADC activity.
- Mechanism-of-Action Studies: Especially useful for studying tissue factor targeting and MMAE-mediated microtubule disruption.
- Comparative ADC Research: Supports evaluation of ADC design, targeting strategies, and experimental performance.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Tisotumab Vedotin combines tissue factor-directed antibody targeting with an MMAE payload and specifically supports ADC research, tissue factor studies, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
